{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-021578","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.550379+00:00","generated_at":"2026-05-15T08:41:38.841582+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Senti Bio FY2025 net loss $61.4M; SENTI-202 gets RMAT, Phase 1 data encouraging","bullets":["Net loss $61.4M for FY2025 ($2.73/share); Q4 loss $14.5M ($0.53/share).","Cash and equivalents $16.4M as of December 31, 2025.","SENTI-202 received RMAT designation for relapsed/refractory AML; updated Phase 1 data show encouraging responses and safety.","R&D expenses $37.6M full year; G&A expenses $26.2M full year, down in Q4 YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-021578","json":"https://secwatch.observer/filing/0001628280-26-021578.json","markdown":"https://secwatch.observer/filing/0001628280-26-021578.md","text":"https://secwatch.observer/filing/0001628280-26-021578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026021578/0001628280-26-021578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026021578/snti-20260327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:41:38.841582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cfdacf395d5f8d4ca54766261e83da141f15a2d3","claim":"Senti Biosciences, Inc. reported the year ended December 31, 2025 results: net income Net loss ... for the full-year 2025 was $61.4 million, or $2.73 per share, EPS $2.73 per share.","evidence_excerpt":"Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026021578/0001628280-26-021578-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Net income","value":"Net loss ... for the full-year 2025 was $61.4 million, or $2.73 per share"},{"label":"EPS","value":"$2.73 per share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}